Comparison of efficacy and safety of secukinumab and adalimumab in the treatment of moderate to severe plaque psoriasis
Objective To analyze the effect and safety of secukinumab and adalimumab in the treatment of moderate to severe plaque psoriasis.Methods 94 cases of moderate to severe plaque psoriasis patients were divided into a control group and a study group according to random number table method,with 47 cases in each group.The control group was treated with adalimumab,and the study group was treated with secukinumab.The psoriasis area and severity index,improvement rate and incidence of adverse reactions were compared between the two groups.Results At 4,8 and 12 weeks after treatment,the psoriasis area and severity index of the study group were(7.55±6.51),(4.60±5.85)and(2.90±5.55)points,and those of the control group were(10.37±6.67),(6.77±6.41)and(3.80±5.75)points.At 4 weeks after treatment,the psoriasis area and severity index of the study group were lower than that of the control group,there was statistical significance(P<0.05).At 8 and 12 weeks after treatment,the psoriasis area and severity index of the two groups were not statistically significant(P>0.05).In the control group,the improvement rate of psoriasis area and severity index at 4 weeks after treatment was(51.13±8.69)%,the improvement rate of psoriasis area and severity index at 8 weeks was(68.10±9.48)%,and the improvement rate of psoriasis area and severity index at 12 weeks was(82.09±9.62)%.In the study group,the improvement rate of psoriasis area and severity index at 4 weeks after treatment was(66.62±9.04)%,the improvement rate of psoriasis area and severity index at 8 weeks after treatment was(79.66±9.88)%,and the improvement rate of psoriasis area and severity index at 12 weeks after treatment was(87.17±10.30)%.The improvement rates of psoriasis area and severity index in the study group at 4,8 and 12 weeks after treatment were significantly higher than those in the control group,and there was statistical significance(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Both secukinumab and adalimumab have significant efficacy in the treatment of moderate to severe plaque psoriasis,with little difference in the probability of adverse reactions and a high safety profile.Secukinumab can be preferred.
SecukinumabAdalimumabModerate to severe plaque psoriasisSafety
NETL
NSTL
万方数据
